Lemme GLP-1 Daily federal class action voluntarily dismissed

A federal class action against Lemme Inc. over its GLP-1 Daily supplement has ended without any court deciding whether the product's marketing claims held up. The case, Robins v. Lemme Inc., No. 1:25-cv-01938, was filed March 9, 2025, in the U.S. District Court for the Southern District of New York and was formally terminated April 16, 2025, after the parties filed a joint stipulation of voluntary dismissal ^[1].

The lawsuit was brought by plaintiff Christina Robins and alleged fraud, according to the case's docketed "cause" listing of diversity-based fraud claims ^[1]. The suit centered on Lemme's GLP-1 Daily supplement and claims that it could increase the body's natural GLP-1 hormone and reduce hunger, the kind of language that echoes the effects of prescription GLP-1 drugs like semaglutide and tirzepatide ^[1]. GLP-1 Daily is a dietary supplement, not an FDA-approved prescription medicine.

Lemme moved to dismiss the case on April 8, 2025, filing a motion and supporting memorandum of law ^[1]. Eight days later, the parties resolved the matter by stipulation rather than through a judge's ruling. The docket shows an initial dismissal filing on April 15 was rejected by the clerk's office because it lacked handwritten signatures from all parties; a corrected version was filed and accepted the next day, April 16 ^[1]. The dismissal was entered under Federal Rule of Civil Procedure 41(a)(1)(A)(ii) and was without prejudice against Lemme, meaning the claims were dropped but not permanently barred from being refiled ^[1].

Because the case ended by stipulation rather than a substantive ruling, no judge in the New York case ever evaluated whether Lemme's claims about GLP-1 Daily were accurate or misleading. The docket does not state why the parties agreed to dismiss, and no settlement terms are described in the available court record ^[1].

A related lawsuit brought by the same plaintiff remains pending in state court. Robins also filed an action, No. 25STCV04635, on February 19, 2025, in Los Angeles Superior Court, before the federal case was filed ^[1]. That case is not shown as resolved in the source material reviewed here.

Why it matters for patients

This dismissal does not confirm or clear Lemme's marketing claims. Because no judge ruled on the merits, consumers are left without a legal finding on whether GLP-1 Daily can do what its name and marketing suggested — raise the body's own GLP-1 levels or meaningfully reduce hunger the way prescription GLP-1 drugs do ^[1]. People comparing over-the-counter supplements marketed with GLP-1-related language to prescription medicines like semaglutide (Ozempic, Wegovy, Rybelsus) or tirzepatide (Mounjaro, Zepbound) should know that a supplement facing this kind of lawsuit has not had its claims validated in court, nor has it undergone the FDA approval process that prescription GLP-1 drugs go through. The case's quiet ending, via a corrected stipulation after an initial signature error, means the underlying factual dispute simply goes unresolved rather than settled in either party's favor ^[1].

What happens next

The federal docket shows no scheduled proceedings after the April 16, 2025 termination ^[1]. What remains unclear from the available record is the current status of the parallel Los Angeles Superior Court case, No. 25STCV04635, filed February 19, 2025, which was not shown as dismissed in the source reviewed ^[1]. It is not yet known whether Robins or another plaintiff will refile similar claims against Lemme, since the federal dismissal was without prejudice ^[1].